Plasma therapy trials for coronavirus patients begin in Karnataka

According to officials, patients who have recovered from COVID-19 have been appealed to come forward as donors, as anti-bodies of cured patients will be used to treat critically ill under this therapy.

PTI

April 25, 2020 / 16:38 IST

Representative image

The Karnataka government on Saturday commenced convalescent plasma therapy clinical trials for 'severe' coronavirus patients in the state.

In a tweet, Medical Education Minister K Sudhakar said, "Happy to announce the commencement of Clinical Trials for Plasma Therapy that holds great promise to treat severely infected #COVID19 patients. Health Min @sriramulubjp & I initiated this significant step at Victoria Hospital today morning."

The Minister, who is also leading government efforts against COVID-19 in Bengaluru and is in charge of the state war room had said Convalescent Plasma Therapy was only for patients who are critical, in intensive care units or on ventilator. Donors have also come forward for this, he had said.

Coronavirus LIVE Updates

According to officials, patients who have recovered from COVID-19 have been appealed to come forward as donors, as anti-bodies of cured patients will be used to treat critically ill under this therapy.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show